Author:
Sri Khagga Bhavya,Fatima Mohammad Saba,Sumakanth Mogili
Reference17 articles.
1. [1] Taylor PC, Keystone EC, Van Der Heijde D, Weinblatt ME, del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652-62.
2. [2] AlRuwaili NS, Mohammad AA, Alnathir HF, Alfeheid MH, Alshammari NN. Illicit Drugs Addiction Among Patients With Chronic Diseases: Simple Review Article. Pharmacophore. 2022;13(3):81-5.
3. [3] Ukibayev J, Datkhayev U, Myrzakozha D, Frantsev A, Karlova E, Nechepurenko Y, et al. Rectal methods of delivery of medical drugs with a protein nature in the therapies of tumor disease. J Adv Pharm Educ Res. 2021;11(1):18-22.
4. [4] DrugBank. [2020, April. 30] Baricitinib. [Online]. Available from: https://go.drugbank.com/drugs/DB11817
5. [5] "Olumiant: EPAR – Product Information" (PDF). European Medicines Agency. 13 February 2017. Archived (PDF) from the original on 12 July 2018. Retrieved 7 June 2017.